Speaker illustration

Professor Douglas Harrington

GuardaHeart Foundation, Irvine (United States of America)

Member of:

European Society of Cardiology

Dr. Douglas Harrington has over 25 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. Dr. Harrington has developed patents for an automated method for image analysis of residual cancer cells, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. Dr. Harrington has developed patents for an automated method for image analysis of residual cancer cells, a patent covering catalytic heavy metal extraction, and a patent pending on biomarker assay for diagnosis and classification of cardiac disease. Throughout his career, Dr. Harrington has remained a Clinical Professor of Pathology at the USC Keck School of medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine and technology development.

Novel biomarker algorithmic panel measuring permutations of immune response to cardiac endothelial injury and global risk factors identifies patients at risk of acute coronary syndrome (ACS)

Event: ESC CONGRESS 2019

Topic: Biomarkers

Session: Acute Coronary Syndromes: Biomarkers

Thumbnail

This platform is supported by

logo Novo Nordisk